AIkido Pharma Inc (AIKI)

[Avoid]

Summary

- 2016 Net income per share attributable to common stockholders, $6.76

- "Spherix has no debt and a lower quarterly burn than in the past 4 years."

- "There are five cases on file, working their way through the judicial system."

- "In addition, our efforts with Equitable have secured the monetization rights to over 100 new patents that are largely unlicensed. "

- Hoth anticipates dramatically shorter time frames for FDA approval because the BioLexa compound uses a combination of two previously approved drugs. 

- O/S 4.9M

- Market Cap 20M - $4

- Aug 2013 $529 share ; the next $KBIO ?

$SPEX